Supplementary material 1. Search Strategy

1 Joint Capsule/

2 Capsula Articularis.mp.

3 Synovial Capsule.mp.

4 articular Capsule.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

5 1 or 2 or 3 or 4

6 Rotator Cuff/

7 Teres Minor.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier synonyms]

8 Subscapularis.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

9 infraspinatus.mp. 1965

10 Supraspinatus.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

11 6 or 7 or 8 or 9 or 10

12 *Cartilage, Articular/

13 Articular Cartilages.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating subheading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

14 Hyaline Cartilage/

15 Hyaline Cartilage$ (ti,ab)

16 *Synovial Membrane/

17 synovial membrane$ (ti,ab)

18 synovium (ti,ab)

19 12 or 13 or 14 or 15 or 16 or 17 or 18

20 *Joint Diseases/

21 joint disease$ (ti,ab)

22 arthrosis (ti,ab)

23 arthropat$ (ti,ab)

24 *arthritis/

25 arthrit$ (ti,ab)

26 *synovitis/

27 Synovial Hypertrop$ (ti,ab)

28 synovial thick$ (ti,ab)

29 20 or 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28

30 BURSITIS/

31 bursit$ (ti,ab)

32 capsulit$ (ti,ab)

33 "frozen should$" (ti,ab)

34 "adhesive capsulit$" (ti,ab)

35 30 or 31 or 32 or 33 or 34

36 Injections, Intra-Articular/

37 intraarticular injection$ (ti,ab)

38 intra-Articular injection$ (ti,ab)

39 VISCOSUPPLEMENTATION/

40 "Viscosupplementation" (ti,ab)

41 "Visco-supplementation" (ti,ab)

42 ("Orthopedic Procedure$" not surg$) (ti,ab)

43 *Hyaluronic Acid/

44 Hyaluronic Acid (ti,ab)

45 "Hyaluron$" (ti,ab)

46 "Amo Vitrax".mp.

47 Vitrax, Amo.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

48 "Biolon".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword 25 heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

49 "hyvisc".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword 1 heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

50 "luronit".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword 1 heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

51 "Amvisc".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

52 *GLYCOSAMINOGLYCANS/

53 "Mucopolysaccharid$" (ti,ab)

54 TRIAMCINOLONE/

55 "Volon".mp.

56 "Aristocort".mp.

57 Triamcinolone Acetonide/

58 "Tricort-40".mp.

59 "Tricort 40".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

60 "Kenalog 40".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

61 Azmacort.mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

62 "Kenacort A".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

63 Triamcinolone hexacetonide.mp. 346

64 "Aristospan".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

65 *Mesenchymal Stromal Cell$/dg, de, and, im, me, pa, ph, re [Diagnostic Imaging, Drug Effects, Enzymology, Immunology, Metabolism, Pathology, Physiology, Radiation Effects]

66 Cel$, Mesenchymal Stromal (ti,ab)

67 Stromal Cell$, Mesenchymal (ti,ab)

68 Mesenchymal Stem Cell.mp.

69 "Mesenchymal Stem Cell$" (ti,ab)

70 limit 69 to "therapy (best balance of sensitivity and specificity)"

71 "Mesenchymal Progenitor Cel$" (ti,ab)

72 limit 71 to "therapy (best balance of sensitivity and specificity)"

73 "Mesenchymal Stromal Cells, Multipotent" (ti,ab)

74 "Multipotent Bone Marrow Stromal Cel$" (ti,ab)

75 "Bone Marrow Stromal Cel$, Multipotent" (ti,ab)

76 "Wharto$ Jelly Cel$" (ti,ab)

77 "Cel$, Wharto$ Jelly".mp. [mp=title, abstract, original title, name of substance word, subject heading word, floating sub-heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]

78 "Multipotent Stem Cel$" (ti,ab)

79 limit 78 to "therapy (best balance of sensitivity and specificity)"

80 "Stem Cel$, Multipotent" (ti,ab)

81 Platelet-Rich Plasma/

82 "Plasma, Platelet-Rich" (ti,ab)

83 "Platelet Rich Plasma" (ti,ab)

84 *Blood Platelets/

85 limit 83 to "therapy (best balance of sensitivity and specificity)"

86 limit 84 to "therapy (best balance of sensitivity and specificity)"

87 "Blood Platelet$" (ti,ab)

88 limit 87 to "therapy (maximizes specificity)"

89 "Platelet$, Blood" (ti,ab)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

RMD Open

90 "Thrombocyte$" (ti,ab)
91 limit 90 to "therapy (maximizes specificity)"
92 "platelet$" (ti,ab)
93 limit 92 to "therapy (maximizes specificity)"
94 *PLASMA/ 11888
95 limit 94 to "therapy (maximizes specificity)"
96 "Plasma$" (ti,ab)
97 limit 96 to "therapy (maximizes specificity)"
98 "Blood Plasma$" (ti,ab)
99 limit 98 to "therapy (maximizes specificity)"
100 "Plasma$, Blood" (ti,ab)
101 "Fresh Frozen Plasma$" (ti,ab)
102 limit 101 to "therapy (maximizes specificity)"
103 "Frozen Plasma$, Fresh" (ti,ab)
104 "Plasma$, Fresh Frozen" (ti,ab)
105 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63 or 64
106 65 or 66 or 67 or 68 or 70 or 72 or 73 or 74 or 75 or 76 or 77 or 79 or 80
107 81 or 82 or 85 or 86 or 88 or 89 or 91 or 93 or 95 or 97 or 99 or 100 or 102 or 103 or 104
108 Yttrium Radioisotopes/
109 "Radioisotope$, Yttrium" (ti,ab)
110 *YTTRIUM/ad, ae, an, bl, me, pk, pd, re, st, tu, th, to, ur [Administration & Dosage, Adverse Effects, Analysis, Blood,
    Metabolism, Pharmacokinetics, Pharmacology, Radiation Effects, Standards,
111 "Yttrium Isotope$" (ti,ab)
112 Radioisotopes (ti,ab)
113 limit 112 to "therapy (best balance of sensitivity and specificity)"
114 "Radiopharmaceuticals" (ti,ab)
115 limit 114 to "therapy (best balance of sensitivity and specificity)"
116 "Radiotherapy Dosage" (ti,ab)
117 "Yttrium-90" (ti,ab)
118 limit 117 to "therapy (best balance of sensitivity and specificity)"
119 "Radioactive Isotope$" (ti,ab)
120 limit 119 to "therapy (best balance of sensitivity and specificity)"
121 Isotope$, Radioactive.mp.
122 "Isotope$, Radioactive" (ti,ab)
123 "Radionuclides" (ti,ab)
124 limit 123 to "therapy (best balance of sensitivity and specificity)"
125 Daughter Isotopes.mp.
126 "Radiogenic Isotopes" (ti,ab)
127 "Isotope$, Radiogenic".mp.
128 "Daughter Nuclides" (ti,ab)
129 "Samarium-153" (ti,ab)
130 Samarium/ad, ae, an, bl, ch, me, pk, pd, po, re, tu, to, ur [Administration & Dosage, Adverse Effects, Analysis, Blood,
    Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Radiation Effects, Therapeutic Use, Toxicity, Urine]
131 153Sm radioisotope.mp.
132 "Samarium hydroxyapatite" (ti,ab)
133 "samarium-153-particulate hydroxyapatite" (ti,ab)
134 *HYDROXYAPATITES/ad, ae, ai, bl, ch, cl, im, me, pk, pd, ph, po, re, tu, to, ur [Administration & Dosage, Adverse Effects,
    Antagonists & Inhibitors, Blood, Chemistry, Classification, Immunology, Metabolism, Pharmacokinetics, Pharmacology,
    Physiology, Poisoning, Radiation Effects, Therapeutic Use, Toxicity, Urine]
135 limit 134 to "therapy (best balance of sensitivity and specificity)
136 "Hydroxyapatite Derivatives" (ti,ab)
137 Dysprosium lithium borate glass.mp.
138 *Osmium Tetroxide/ad, ae, ch, me, pk, pd, po, tu, to [Administration & Dosage, Adverse Effects, Chemistry, Metabolism,
    123 Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Toxicity]
139 Tetroxide, Osmium (ti,ab)
140 "Osmic Acid" (ti,ab)
141 limit 140 to "therapy (maximizes specificity)"
142 *Rhenium/ad, ae, bl, ch, im, me, py, pk, pd, re, tu, to, ur [Administration & Dosage, Adverse Effects, Blood, Chemistry,
    Immunology, Metabolism, Pathogenicity, Pharmacokinetics, Pharmacology, Radiation Effects, Therapeutic Use, Toxicity,
    Urine]
143 "Rhenium-186" (ti,ab)
144 limit 143 to "therapy (maximizes sensitivity)"
145 "Erbium-169" (ti,ab)

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

146 "Erbium" (ti,ab)
147 limit 146 to "therapy (best balance of sensitivity and specificity)"
148 *ERBIUM/ad, ae, an, bl, ch, me, pk, pd, re, tu, to [Administration & Dosage, Adverse Effects, Analysis, Blood, Chemistry, 403 Metabolism, Pharmacokinetics, Pharmacology, Radiation Effects, Therapeutic Use, Toxicity]
149 "Er-169" (ti,ab)
150 Citric Acid/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Toxicity, Urine]
151 limit 150 to "therapy (best balance of sensitivity and specificity)"
152 "Citrates" (ti,ab)
153 SYNOVITIS/rt [Radiotherapy]
154 Synovial Membrane/re [Radiation Effects]
155 SYNOVECTOMY/
156 "synovectom$" (ti,ab)
157 "Synovium Resectio$" (ti,ab)
158 *ELECTRONS/ae, tu [Adverse Effects, Therapeutic Use]
159 "Electron" (ti,ab)
160 limit 159 to "therapy (maximizes specificity)"
161 "Negatron$" (ti,ab)
162 negatron.mp.
163 "positron$" (ti,ab)
164 limit 163 to "therapy (maximizes specificity)"
165 "Fast Electron$" (ti,ab)
166 "Electron$, Fast" (ti,ab)
167 *Organometallic Compounds/ad, ae, aa, ai, bl, cf, ch, cl, im, me, pk, pd, ph, po, re, tu, th, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Cerebrospinal Fluid, Chemistry, Classification, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Physiology, Poisoning, Radiation Effects, Therapeutic Use, Therapy, Toxicity, Urine] Metabolism, Pharmacokinetics, Pharmacology, Physiology, Poisoning, Radiation Effects, Therapeutic Use, Therapy, Toxicity, Urine]
168 limit 167 to "therapy (maximizes specificity)"
169 "Compounds, Organometallic" (ti,ab)
170 "Metallo-Organic Compounds" (ti,ab)
171 "Metalloorganic Compounds" (ti,ab)
172 Compounds, Metalloorganic (ti,ab)
173 108 or 109 or 110 or 111 or 113 or 115 or 116 or 118 or 120 or 121 or 122 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133 or 135 or 136 or 137 or 138 or 139 or 141 or 142 or 144 or 145 or 147 or 148 or 149 or 151 or 152 or 153 or 154 or 155 or 156 or 157 or 158 or 160 or 161 or 162 or 164 or 165 or 166 or 168 or 169 or 170 or 171 or 172
174 Anesthetics, Local/ad, ae, bl, ch, cl, co, im, me, pk, pd, ph, po, re, tu, th, to, ur [Administration & Dosage, Adverse Effects, Blood, Chemistry, Classification, Complications, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Physiology, Poisoning, Radiation Effects, Therapeutic Use, Therapy, Toxicity, Urine]
175 limit 174 to "therapy (best balance of sensitivity and specificity)"
176 *ANESTHETICS/ad, ae, bl, ch, co, im, me, pk, pd, ph, po, sn, tu, th, to, ur [Administration & Dosage, Adverse Effects, Blood, Chemistry, Complications, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Physiology, Poisoning, Statistics & Numerical Data, Therapeutic Use, Therapy, Toxicity, Urine]
177 limit 176 to "therapy (maximizes specificity)"
178 "Anesthetic Drug$" (ti,ab)
179 "Drugs, Anesthetic" (ti,ab)
180 "Anesthetic Agents" (ti,ab)
181 "Anesthetic Effect$" (ti,ab)
182 "Effect$, Anesthetic".mp.
183 Benzocaine/ad, ae, aa, bl, ch, im, me, pk, pd, po, tu, th, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Therapy, Toxicity, Urine]
184 *Benzyl Alcohol/ad, ae, bl, ch, im, me, pk, pd, re, tu, to [Administration & Dosage, Adverse Effects, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Radiation Effects, Therapeutic Use, Toxicity]
185 *BUPIVACAINE/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]
186 *Carticaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

187 *Cocaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

188 limit 187 to "therapy (best balance of sensitivity and specificity)"

189 *Dibucaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

190 *Diphenhydramine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

191 *Ethyl Chloride/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

192 *Etidocaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

193 *Lidocaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

194 *Mepivacaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

195 *Prilocaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

196 *Procaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

197 *Propoxycaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

198 *Tetracaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

199 *Tetrodotoxin/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

200 *Trimecaine/ad, ae, aa, ai, bl, ch, im, me, pk, pd, po, sd, tu, to, ur [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Supply & Distribution, Therapeutic Use, Toxicity, Urine]

201 175 or 177 or 178 or 179 or 180 or 181 or 182 or 183 or 184 or 185 or 186 or 188 or 189 or 190 or 191 or 192 or 193 or 194 or 195 or 196 or 197 or 198 or 199 or 200

202 *Analgesics, Opioid/ad, ae, ag, ai, bl, ch, cl, im, me, pk, pd, po, tu, to, ur [Administration & Dosage, Adverse Effects, Agonists, Antagonists & Inhibitors, Blood, Chemistry, Classification, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Toxicity, Urine]

203 limit 202 to "therapy (best balance of sensitivity and specificity)"

204 "Opioid Analgesics" (ti,ab)

205 "Partial Opioid Agonist$" (ti,ab)

206 "Opioid Agonists, Partial" (ti,ab)

207 "Opioids" (ti,ab)

208 limit 207 to "therapy (best balance of sensitivity and specificity)"

209 "Opioid Partial Agonists" (ti,ab)

210 ("Agonists" and "Opioid Partial") (ti,ab)

211 ("Partial Agonists" and "Opioid") (ti,ab)

212 "Full Opioid Agonists" (ti,ab)

213 ("Agonists" and "Full Opioid") (ti,ab)

214 ("Opioid Agonists" and "Full") (ti,ab)

215 "Opioid Full Agonists" (ti,ab)

216 ("Agonists" and "Opioid Full") (ti,ab)

217 ("Full Agonists" and "Opioid") (ti,ab)

218 "Opioid Mixed Agonist-Antagonists" (ti,ab)

219 ("Agonist-Antagonists" and "Opioid Mixed") (ti,ab)

220 ("Mixed Agonist-Antagonists" and "Opioid") (ti,ab)

221 "Opioid Mixed Agonist Antagonists" (ti,ab)

222 *Alfentanil/ad, ae, aa, ai, bl, me, pk, pd, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Metabolism, Pharmacokinetics, Pharmacology, Therapeutic Use, Toxicity]

223 *Alphaprodine/ad, ae, aa, ai, bl, me, pk, pd, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Metabolism, Pharmacokinetics, Pharmacology, Therapeutic Use, Toxicity]

224 *Buprenorphine/ad, ae, aa, ai, bl, me, pk, pd, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Metabolism, Pharmacokinetics, Pharmacology, Therapeutic Use, Toxicity]

225 *Buprenorphine, Naloxone Drug Combination/ad, ae, aa, ai, bl, me, pk, pd, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Antagonists & Inhibitors, Blood, Metabolism, Pharmacokinetics, Pharmacology, Therapeutic Use, Toxicity]

226 *BUPRENORPHINE, NALOXONE DRUG COMBINATION/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

227 *Butorphanol/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, 620 Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

228 *Codeine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

229 *Dextromoramide/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, 71 Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

230 *Dextropropoxyphene/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

231 *Dihydromorphine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, 44 Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

232 *Diphenoxylate/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, 113 Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

233 *Ethylketocyclazocine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

234 *Ethylmorphine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

235 *Etorphine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

236 *Fentanyl/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

237 *Heroin/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

238 limit 237 to "therapy (maximizes specificity)"

239 *Hydrocodone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

240 *Hydromorphone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, 557 Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

241 *Levorphanol/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

242 *Meperidine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

243 *Meptazinol/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

244 *Methadone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

245 *Methadyl Acetate/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

246 *Morphine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

247 limit 246 to "therapy (maximizes specificity)"

248 *Nalbuphine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

249 *Opiate Alkaloids/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

250 *Opium/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

251 *Oxycodone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

252 *Oxymorphone/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, 172 Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

253 *Pentazocine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

254 *Phenoperidine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

255 *Pirinitramide/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

256 *Promedol/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

257 *Sufentanil/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

258 *Tilidine/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

259 *Tramadol/ad, ae, ch, me, pk, pd, po, tu, ur [Administration & Dosage, Adverse Effects, Chemistry, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Urine]

260 limit 259 to "therapy (best balance of sensitivity and specificity)"

*MORPHINE/ad, ae, ag, ai, bl, ch, im, ip, me, pk, pd, po, tu, th, to [Administration & Dosage, Adverse Effects, Agonists,

261 Antagonists & Inhibitors, Blood, Chemistry, Immunology, Isolation & Purification, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Therapy, Toxicity]

262 limit 261 to "therapy (maximizes specificity)"

263 *MORPHINE DERIVATIVES/ad, ae, ai, bl, ch, im, me, pk, pd, po, tu, to [Administration & Dosage, Adverse Effects, Antagonists & 812 Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Toxicity]

264 (Receptor$ and Opioid$ and mu) (ti,ab)

265 limit 264 to "therapy (maximizes specificity)"

266 ("Opioid Receptors" and "mu") (ti,ab)

267 limit 266 to "therapy (maximizes specificity)"

268 "mu Opioid Receptors" (ti,ab)

269 ("Receptors" and "mu Opioid") (ti,ab)

270 "mu Receptor" (ti,ab)

271 (Receptor$ and mu) (ti,ab)

272 "mu Receptors" (ti,ab)

273 "mu Opioid Receptor" (ti,ab)

274 ("Opioid Receptor" and "mu") (ti,ab)

275 ("Receptor" and "mu Opioid") (ti,ab)

276 ("Receptor$" and "Morphine") (ti,ab)

277 "Morphine Receptor$" (ti,ab)

278 morphine-like compounds.mp.

279 non peptide morphine like compound$.mp.

280 limit 271 to "therapy (best balance of sensitivity and specificity)"

281 limit 276 to "therapy (best balance of sensitivity and specificity)"

282 203 or 204 or 205 or 206 or 208 or 209 or 210 or 211 or 212 or 213 or 214 or 215 or 216 or 217 or 218 or 219 or 220 or 221 or 222 or 223 or 224 or 225 or 226 or 227 or 228 or 229 or 230 or 231 or 232 or 233 or 234 or 235 or 236 or 238 or 239 or 240 or 241 or 242 or 243 or 244 or 245 or 247 or 248 or 249 or 250 or 251 or 252 or 253 or 254 or 255 or 256 or 257 or 258 or 260 or 262 or 263 or 265 or 267 or 268 or 269 or 270 or 272 or 273 or 274 or 275 or 277 or 278 or 279 or 280 or 281

283 *Antirheumatic Agents/ad, ae, ai, bl, ch, im, me, pk, pd, po, tu, to [Administration & Dosage, Adverse Effects, Antagonists & 14876 Inhibitors, Blood, Chemistry, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Poisoning, Therapeutic Use, Toxicity]

284 limit 283 to "therapy (best balance of sensitivity and specificity)"

285 "Anti-Rheumatic Drugs" (ti,ab)

286 "Antirheumatic Drugs" (ti,ab)

287 "Anti-Rheumatic Agents" (ti,ab)

288 "Anti Rheumatic Agents" (ti,ab)

289 ("Antirheumatic Drugs" and "Disease-Modifying") (ti,ab)

290 ("Antirheumatic Drug$" and "Disease Modifying") (ti,ab)

291 "DMARD" (ti,ab)

292 "Disease-Modifying Antirheumatic Drugs" (ti,ab)

293 ("Anti-Rheumatic Agents" and "Non-Steroidal") (ti,ab)

294 ("Anti Rheumatic Agents" and "Non-Steroidal") (ti,ab)

295 "Non-Steroidal Anti-Rheumatic Agents" (ti,ab)

296 *ALLOPURINOL/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

297 *Abatacept/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

298 *Adalimumab/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

299 *Adapalene/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

300*Adapalene, Benzoyl Peroxide Drug Combination/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

301 *Antipyrine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

302 *Apazone/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

303 *Ampyrone/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

304 *Aspirin/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

305 *Auranofin/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

306 *Aurothioglucose/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

307 *Azathioprine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

308 *Bufexamac/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

309 *Celecoxib/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

310 *Certolizumab Pegol/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

311 *Chloroquine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

312 *Clonixin/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

313 *Colchicine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

314 *Curcumin/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

315 limit 314 to "therapy (best balance of sensitivity and specificity)" 236

316 *Cyclophosphamide/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

317 *Cyclosporine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

318 *Diclofenac/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

319 *Diflunisal/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

320 *Epirizole/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

321 *Etanercept/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

322 *Etodolac/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

323 *Fenoprofen/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

324 *Feprazone/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

325 *Flurbiprofen/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

326 *Gold Sodium Thiomalate/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & 796 Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

327 *Gold Sodium Thiosulfate/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

328 *Halofenate/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

329 *Hydroxychloroquine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

330 *Ibuprofen/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

331 *Indomethacin/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis,Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

332 *Indoprofen/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

333 *Infliximab/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

334 Interleukin 1 Receptor Antagonist Protein/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

335 *Interleukin-4 ad, ae, aa, an, cs, im, pk, pd, ph, tu, to/ [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, 0 Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

336 *Ketoprofen/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

337 *Dipyrone/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

338 *Ketorolac/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

339 *Ketorolac Tromethamine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

340 *Masoprocol/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

341 *Meclofenamic Acid/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

342 *Mefenamic Acid/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

343 *Mesalamine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

344 *Methotrexate/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

345 *Naproxen/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

346 *Niflumic Acid/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

347 *Oxyphenbutazone/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

348 *Penicillamine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

349 *Phenylbutazone/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

350 *Piroxicam/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

351 *Rituximab/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

352 *Salicylates/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

353 *Sulfasalazine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

354 *Sulfinpyrazone/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

355 *Sulindac/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

356 *Sodium Salicylate/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

357 *Tolmetin/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

358 *Suprofen/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

359 *Zoxazolamine/ad, ae, aa, an, cs, im, pk, pd, ph, tu, to [Administration & Dosage, Adverse Effects, Analogs & Derivatives, Analysis, Chemical Synthesis, Immunology, Pharmacokinetics, Pharmacology, Physiology, Therapeutic Use, Toxicity]

360 "bucillamine" (ti,ab)

361 "dexketoprofen trometamol" (ti,ab)

362 etoricoxib (ti,ab)

363 "leflunomide" (ti,ab)

364 "meloxicam" (ti,ab)

365 *Immunosuppressive Agents/ad, ae, ag, an, ai, bl, ch, de, im, me, pk, pd, ph, po, tu, to [Administration & Dosage, Adverse Effects, Agonists, Analysis, Antagonists & Inhibitors, Blood, Chemistry, Drug Effects, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Physiology, Poisoning, Therapeutic Use, Toxicity]

366 ("Agents" and "Immunosuppressive") (ti,ab)

367 limit 365 to "therapy (best balance of sensitivity and specificity)"

368 "Immunosuppressants" (ti,ab)

369 "MAb cA2" (ti,ab)

370 "Monoclonal Antibody cA2" (ti,ab)

371 ("cA2" and "Monoclonal Antibody") (ti,ab)

372 Remicade (ti,ab)

*Antibodies, Monoclonal/ad, ae, an, ai, bl, ch, de, im, me, pk, pd, ph, po, tu, to [Administration & Dosage, Adverse Effects,

373 Analysis, Antagonists & Inhibitors, Blood, Chemistry, Drug Effects, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Physiology, Poisoning, Therapeutic Use, Toxicity]

374 limit 373 to "therapy (best balance of sensitivity and specificity)"

375 "Monoclonal Antibodies" (ti,ab) 94529

376 limit 375 to "therapy (best balance of sensitivity and specificity)"

377 *Tumor Necrosis Factor-alpha/ad, ae, ag, ai, bl, ch, de, im, me, pk, pd, ph, po, re, tu, to [Administration & Dosage, Adverse Effects, Agonists, Antagonists & Inhibitors, Blood, Chemistry, Drug Effects, Immunology, Metabolism, Pharmacokinetics, Pharmacology, Physiology, Poisoning, Radiation Effects, Therapeutic Use, Toxicity]

378 limit 377 to "therapy (best balance of sensitivity and specificity)"

379 "Tumor Necrosis Factor alpha" (ti,ab)

380 "Cachectin" (ti,ab)

381 ("Cachectin" and "Tumor Necrosis Factor") (ti,ab)

382 "Cachectin Tumor Necrosis Factor" (ti,ab)

383 "Tumor Necrosis Factor Ligand Superfamily Member 2" (ti,ab)

384 "TNFalpha" (ti,ab)

385 limit 384 to "therapy (maximizes specificity)"

386 "CT-P13 " (ti,ab)

387 ("Antibodies" and "Monoclonal" and "Humanized") (ti,ab)

388 ("Antibodies" and "Humanized") (ti,ab)

389 "Humanized Antibodies" (ti,ab)

390 ("Antibodies" and "Monoclonal" and "Murine-Derived") (ti,ab)

391 ("Murine-Derived" and "Monoclonal" and "Antibodies") (ti,ab)

392 ("Antibodies" and "Murine-Derived" and "Monoclonal") (ti,ab)

393 ("Monoclonal Antibodies" and "Murine-Derived") (ti,ab)

394 "D2E7 Antibody" (ti,ab)

395 ("Antibody" and "D2E7") (ti,ab)

396 Humira (ti,ab)

397 ("Receptors" AND "Tumor Necrosis Factor")(TI,AB

398 limit 397 to "therapy (best balance of sensitivity and specificity)"

399 ("Receptors" and "Cachectin") (ti,ab)

400 "Tumor Necrosis Factor Receptors" (ti,ab)

401 "TNF Receptor" (ti,ab)

402 limit 401 to "therapy (best balance of sensitivity and specificity)"

403 "Tumor Necrosis Factor Receptor" (ti,ab)

404 "Cachectin Receptors" (ti,ab)

405 ("Receptors" and "TNF") (ti,ab)

406 limit 405 to "therapy (maximizes specificity)"

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

407 284 or 285 or 286 or 287 or 288 or 289 or 290 or 291 or 292 or 293 or 294 or 295 or 296 or 297 or 298 or 299 or 300 or 301 or 302 or 303 or 304 or 305 or 306 or 307 or 308 or 309 or 310 or 311 or 312 or 313 or 314 or 315 or 316 or 317 or 318 or 319 or 320 or 321 or 322 or 323 or 324 or 325 or 326 or 327 or 328 or 329 or 330 or 331 or 332 or 333 or 334 or 335 or 336 or 337 or 338 or 339 or 340 or 341 or 342 or 343 or 344 or 345 or 346 or 347 or 348 or 349 or 350 or 351 or 352 or 353 or 354 or 355 or 356 or 357 or 259132 358 or 359 or 360 or 361 or 362 or 363 or 364 or 366 or 367 or 368 or 369 or 370 or 371 or 372 or 374 or 376 or 378 or 379 or 380 or 381 or 382 or 383 or 385 or 386 or 387 or 388 or 389 or 390 or 391 or 392 or 393 or 394 or 395 or 396 or 398 or 399 or 400 or 401 or 402 or 403 or 404 or 405 or 406

408 "Synovial Hypertrophy" (ti,ab)
409 "Radiosynoviorthesis" (ti,ab)
410 "Radiosynovectomy" (ti,ab)
411 "169Er-citrate" (ti,ab)
412 "Intraarticular Morphine" (ti,ab)
413 "Intraarticular opioids" (ti,ab)
414 "Intraarticular anesthetics" (ti,ab)
415 "Intraarticular glucocorticoids" (ti,ab)
416 "Dry Needling" (ti,ab)
417 Meta-Analysis as Topic/
418 meta analy$.tw.
419 Meta-Analysis/
420 (systematic adj (review$1 or overview$1)).tw.
421 exp Review Literature as Topic/
422 metaanaly$.tw.
423 cochrane.ab.
424 embase.ab.
425 (psychlit or psyclit).ab.
426 (psychinfo or psycinfo).ab.
427 (cinahl or cinhal).ab.
428 science citation index.ab.
429 bids.ab.
430 417 or 418 or 419 or 420 or 421 or 422
431 cancerlit.ab.
432 423 or 424 or 425 or 426 or 427 or 428 or 429 or 431
433 reference list$.ab.
434 bibliograph$.ab.
435 hand-search$.ab.
436 relevant journals.ab.
437 manual search$.ab.
438 433 or 434 or 435 or 436 or 437
439 selection criteria.ab.
440 data extraction.ab.
441 439 or 440
442 Review/
443 441 or 442
444 Comment/
445 Letter/
446 Editorial/
447 animal/
448 human/
449 447 not (447 and 448)
450 444 or 445 or 446 or 449
451 430 or 432 or 438 or 443
452 451 not 450
453 exp Child/
454 exp pediatrics/
455 child*.ti,ab.
456 exp infant/
457 infan*.ti,ab.
458 (baby or babies).ti,ab.
459 "adolescent"/ or adolescen*.ti,ab.
460 (pediatric*1 or paediatric*1).ti,ab.
461 (neonat* or newborn*).ti,ab.
462 453 or 454 or 455 or 456 or 457 or 458 or 459 or 460 or 461
463 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49 or 50 or 51 or 52 or 53

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

RMD Open

464 36 or 37 or 38
465 105 or 106 or 107 or 173 or 201 or 282 or 407 or 463
466 5 or 11 or 19 or 29 or 35
467 464 and 465
468 452 and 466 and 467
469 468 not 462

Supplementary Material 2. List of excluded studies

Studies	Reason for exclusion
Avenoso A, et al. Life Sciences. 2018; 193:132-40 Beitzel K, et al. Arthroscopy. 2013;29(10):1702-1711 Boffa A, et al. Int Orthop. 2020;10.1007/s00264-020-04689-5 Chen LH, et al. Int J Boil Macrogol. 2018; 116:572-84 Cheng OT, et al. Pain Med. 2012;13(6):740-53 Filardo G, et al. Arthroscopy. 2013;21(8):1717-29 Gross C, et al. Sports Health. 2013;5(2):153-9 Han YH, et al. Medicine. 2018;97(44):e13049 Jevotovsky DS, et al. *Osteoarthritis Cartilage*. 2018;26(6):711-729 Jong BY, et al. Clin Sports Med. 2018;37(4):537-48 Klett R, et al. *Rheumatology (Oxford)*. 2007;46(10):1531-1537 Liu G, et al. Clin J Pain. 2018;34(10):967-974 Migliore A. Clin Med Insights Arthritis Musculoskelet Disord.2010;3:55-68 O'Hanlon CE, et al. Syst Rev. 2016;5(1):186 Richards MM, et al. Phys Sportsmed.2016;44(2):101-8 Samson DJ, et al. Evid Rep Technol Assess (Full Rep). 2007;(157):1-157 Van den Bekerom MP, et al. Arch Orthop Trauma Surg. 2008;128(8):815-823	Wrong study type
Arroll B, et al. Br J Gen Pract. 2005;55(512):224-228 Garg N, et al. Clin Rheumatol. 2014;33(12):1695-706 Gaujoux-Viala C, et al. Ann Rheum Dis. 2009;68(12):1843-1849 Helliwell PS. J Rheumatol. 2006;33(7):1439-41 Saltzman BM, et al. Am J Sports Med. 2017;45(11):2647-53 Soriano ER, et al. J Rheumatol. 2006;33(7):1422-30 Sun Y, et al. Medicine (Baltimore). 2015;94(50):e2216 Sun Y, et al. *Medicine (Baltimore)*. 2016;95(20):e3469 Van der Heijden GJ, et al. *Br J Gen Pract*. 1996;46(406):309-316 Xiao RC, et al. Clin J Sport Med. 2017;27(3):308-20	Wrong Intervention
Bannuru RR, et al. *Cartilage*. 2016;7(4):322-332 Campbell KA, et al. Arthroscopy. 2015;1(11):2213-21 Cui GH, et al. *Exp Ther Med*. 2016;12(5):3390-3400 Dold AP, et al. Clin J Sport Med. 2014;24(1):31-43 Dong Y, et al. *Clin Rheumatol*. 2020;10.1007/s10067-020-05185-2 Ha CW, et al. *Arthroscopy*. 2019;35(1):277-288.e2 Harris JD, et al. Int J Shoulder Surg. 2011;5(2):31-37 Jones G, et al. *Aust N Z J Med*. 1993;23(3):272-275 Kim SH, et al. *Arch Orthop Trauma Surg*. 2019;139(7):971-980 Kresnik E, et al. Nucl Med Commun. 2002;23(7):683-8 Lin MT, et al. *Arch Phys Med Rehabil*. 2018;99(7):1383-1394.e6 Papalia R, et al. J Boil Regul Homeost Agents. 2017;31(4 Suppl 2):23-32 Pas HI, et al. Br J Sports Med. 2017;51(15):1125-1133 Shi WJ, et al. Phys Sportsmed. 2017;45(3):203-223 Tietze DC, et al. Phys Sportsmed. 2014;42(2):27-37 Van der Zant FM, et al. Clin Exp Rheumatol. 2009;27(1):130-139 Xia P, et al. *Int Orthop*. 2015;39(12):2363-2372 Yubo M, et al. *Plos One*. 2017;12(4):e0175449 Zhong HM, et al. *Biomed Res Int*. 2020 Feb 24;2020:6320154	Wrong inclusion criteria
Ajlani H, et al. Tunis Med. 2008;86(6):591-594	Not available in accepted languages